Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Levitt et al., Clinical Infectious Diseases, doi:10.1093/cid/ciad187
https://c19early.org/levitt.html